Grifols SA
Company Profile
Business description
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Contact
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935710500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,822
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
stocks
Insignia Financial: Revised deal still attractive
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,979.40 | 22.00 | -0.24% |
CAC 40 | 7,813.97 | 36.46 | -0.46% |
DAX 40 | 24,292.55 | 51.73 | 0.21% |
Dow JONES (US) | 44,766.33 | 243.96 | -0.54% |
FTSE 100 | 9,144.95 | 83.46 | 0.92% |
HKSE | 25,667.18 | 129.11 | 0.51% |
NASDAQ | 21,059.31 | 39.29 | 0.19% |
Nikkei 225 | 41,826.34 | 655.02 | 1.59% |
NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
S&P 500 | 6,367.96 | 9.05 | 0.14% |
S&P/ASX 200 | 8,709.40 | 27.80 | -0.32% |
SSE Composite Index | 3,605.73 | 23.43 | 0.65% |